This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-2023v1 69/5/1951    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dallas, N. A. Articles by Ellis, L. M. Search for Related Content PubMed PubMed Citation Articles by Dallas, N. A. Articles by Ellis, L. M.

Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition

Departments of ¹ Surgical Oncology and ² Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Lee M. Ellis, Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Unit 444, P. O. Box 301402, Houston, TX 77230-1402. Phone: 713-792-6926; Fax: 713-792-4689; E-mail: lellis{at}mdanderson.org.

Key Words: chemoresistance • colorectal cancer • IGF-IR

5-Fluorouracil (5FU) and oxaliplatin are standard therapy for metastatic colorectal cancer (CRC), but the development of chemoresistance is inevitable. Because cancer stem cells (CSC) are hypothesized to be chemoresistant, we investigated CSC properties in newly developed chemoresistant CRC cell lines and sought to identify targets for therapy. The human CRC cell line HT29 was exposed to increasing doses of 5FU (HT29/5FU-R) or oxaliplatin (HT29/OxR) to achieve resistance at clinically relevant doses. Western blotting and flow cytometry were done to determine molecular alterations. The insulin-like growth factor-I receptor (IGF-IR) monoclonal antibody (mAb) AVE-1642 was used to inhibit signaling in vitro and in vivo using murine xenograft models. HT29/5FU-R and HT29/OxR showed 16- to 30-fold enrichment of CD133⁺ cells and 2-fold enrichment of CD44⁺ cells (putative CRC CSC markers). Resistant cells were enriched 5- to 22-fold for double-positive (CD133⁺/CD44⁺) cells. Consistent with the CSC phenotype, resistant cells exhibited a decrease in cellular proliferation in vitro (47–59%; P < 0.05). Phosphorylated and total IGF-IR levels were increased in resistant cell lines. HT29/5FU-R and HT29/OxR cells were 5-fold more responsive to IGF-IR inhibition relative to parental cells (P < 0.01) in vitro. Tumors derived from HT29/OxR cells showed significantly greater growth inhibition in response to an IGF-IR mAb than did parental cells (P < 0.05). Chemoresistant CRC cells are enriched for CSC markers and the CSC phenotype. Chemotherapy-induced IGF-IR activation provided for enhanced sensitivity to IGF-IR–targeted therapy. Identification of CSC targets presents a novel therapeutic approach in this disease. [Cancer Res 2009;69(5):1951–7]

This article has been cited by other articles:

				J. Zha, C. O'Brien, H. Savage, L.-Y. Huw, F. Zhong, L. Berry, G. D. Lewis Phillips, E. Luis, G. Cavet, X. Hu, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Mol. Cancer Ther., August 1, 2009; 8(8): 2110 - 2121. [Abstract] [Full Text] [PDF]